Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
ZymoGenetics Licenses Antibody, Cuts Staff
by Rick Mullin
December 14, 2009
| A version of this story appeared in
Volume 87, Issue 50
ZymoGenetics has signed a licensing agreement under which Novo Nordisk will gain worldwide rights to IL-21 mAb, a fully human monoclonal antibody being developed as a treatment for autoimmune and inflammatory diseases. Novo, which has had intellectual property rights to IL-21 mAb outside North America since 2001, will pay ZymoGenetics $24 million up front. Additional milestone payments could reach $157.5 million. Separately, ZymoGenetics will eliminate 52 jobs, a 15% workforce reduction, in an effort to cut costs by focusing on projects furthest along in development.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter